COVAX says India’s Serum Institute bound to supply virus vaccines

Featured Journal Content

 

COVAX

COVAX says India’s Serum Institute bound to supply virus vaccines
By Krishna N. Das
April 9, 2021
NEW DELHI (Reuters) – The Serum Institute of India (SII) is legally compelled to ship coronavirus vaccine to global vaccine sharing facility COVAX, its co-lead Gavi has told Reuters, a provision that could complicate the firm’s efforts to boost domestic supplies.

India, where infections have surged to 13.06 million, suspended all major exports of vaccines last month to fill demand at home, forcing the world’s biggest vaccine maker to divert nearly all its production to the domestic market.

“The agreement is legally binding and served as a basis for the first-round allocation document, which has been communicated to all participating economies,” a Gavi spokeswoman said in an email. The pact specified Gavi would receive from SII 1.1 billion doses of either the AstraZeneca vaccine or that of Novavax, with 200 million committed, and the rest on option.

SII partner AstraZeneca has already issued it a legal notice over delays to other shipments, even as many Indian states have complained of a shortage facing priority recipients.

Gavi said its pact with SII took effect when the World Health Organization approved the AstraZeneca shot on Feb. 15, after a source said SII had originally been supposed to send doses to COVAX only from May.

“SII has pledged that, alongside supplying India, it will prioritise the COVAX multilateral solution for equitable distribution,” Gavi added.

COVAX had expected here a total of more than 100 million doses from SII between February and May, excluding supplies for India, but has so far received here only about 18.2 million.

Serum has sent another 10 million doses to the Indian government through COVAX, Gavi said. Gavi did not respond on Friday to questions about what now lies ahead. SII also did not immediately respond to a request for comment…